Study backs Theralux therapy for non-Hodgkin's lymphoma
This article was originally published in Clinica
Executive Summary
Celmed BioSciences' ex vivo photodynamic cell therapy completely eradicated cancer cells from autologous stem cell grafts in 88% percent of patients with non-Hodgkin's lymphoma (NHL), interim results of an ongoing clinical study have revealed.